Pluronic F127-modified liposome-containing tacrolimus-cyclodextrin inclusion complexes: Improved solubility, cellular uptake and intestinal penetration

Journal of Pharmacy and Pharmacology

Volumn 65, Issue 8, 2013, Pages 1107-1117

  Zhu, Quanlei ^a   Guo, Tao ^a   Xia, Dengning ^a   Li, Xiuying ^a   Zhu, Chunliu ^a   Li, Haiyan ^a   Ouyang, Defang ^b   Zhang, Jiwen ^a   Gan, Yong ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b ASTON UNIVERSITY   (United Kingdom)

Author keywords

cellular uptake; cyclodextrin inclusion complex; molecular modelling; Pluronic F127 modified liposomes; solubility; tacrolimus

Indexed keywords

CYCLODEXTRIN; LIPOSOME; NANOCARRIER; PHOSPHATE; POLOXAMER; TACROLIMUS; TAUROCHOLIC ACID;

ANIMAL EXPERIMENT; ARTICLE; CELL LEVEL; CELL STRAIN CACO 2; CHEMICAL BINDING; CHEMICAL MODIFICATION; CONTROLLED STUDY; DILUTION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG SYNTHESIS; DRUG UPTAKE; GASTROINTESTINAL TRACT; HUMAN; HUMAN CELL; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; LIPID MEMBRANE; MALE; MOLECULAR MODEL; NONHUMAN; RAT; SIMULATION; STOMACH JUICE;

CELLULAR UPTAKE; CYCLODEXTRIN INCLUSION COMPLEX; MOLECULAR MODELLING; PLURONIC F127-MODIFIED LIPOSOMES; SOLUBILITY; TACROLIMUS;

ANIMALS; BETA-CYCLODEXTRINS; CACO-2 CELLS; CELL MEMBRANE; DRUG CARRIERS; DRUG COMPOUNDING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; LIPOSOMES; MALE; MODELS, MOLECULAR; POLOXAMER; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; TACROLIMUS;

EID: 84880133034     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12074     Document Type: Article

References (44)

1. Davis ME, Brewster ME,. Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov 2004; 12: 1023-1035.
2. Loftsson T, Brewster ME,. Pharmaceutical applications of cyclodextrins: basic science and product development. J Pharm Pharmacol 2010; 11: 1607-1621.
3. Dahan A, Hoffman A,. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J Control Release 2008; 1: 1-10.
4. Carrier RL, et al. The utility of cyclodextrins for enhancing oral bioavailability. J Control Release 2007; 2: 78-99.
5. Hidetoshi A, et al. Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats. J Pharm Sci 2001; 6: 690-701.
6. Chen W, et al. Development and evaluation of novel itraconazole-loaded intravenous nanoparticles. Int J Pharm 2008; 1-2: 133-140.
7. Valentino JS, et al. Mechanisms of drug release from cyclodextrin complexes. Adv Drug Del Rev 1999; 36: 3-16.
8. Yi Y, et al. A mixed polymeric micellar formulation of itraconazole: characteristics, toxicity and pharmacokinetics. J Control Release 2007; 1: 59-67.
9. Veiga F, et al. Oral bioavailability and hypoglycaemic activity of tolbutamide/cyclodextrin inclusion complexes. Int J Pharm 2000; 1-2: 165-171.
10. Rajeswari C, et al. Cyclodextrins in drug delivery: an updated review. AAPS PharmSciTech 2005; 2: E329-E357.
11. Agueros M, et al. Combined hydroxypropyl-beta-cyclodextrin and poly(anhydride) nanoparticles improve the oral permeability of paclitaxel. Eur J Pharm Sci 2009; 4: 405-413.
12. Agüeros M, et al. Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles. J Control Release 2010; 1: 2-8.
13. Arun R, et al. Cyclodextrin as drug carrier molecule: a review. Sci Pharm 2008; 4: 567-598.
14. Loftsson T, Brewster ME,. Pharmaceutical applications of cyclodextrins: effects on drug permeation through biological membranes. J Pharm Pharmacol 2011; 9: 1119-1135.
15. Lai SK, et al. Micro- and macrorheology of mucus. Adv Drug Deliv Rev 2009; 2: 86-100.
16. Lai SK, et al. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 2009; 2: 158-171.
17. Ortiz Mellet C, et al. Cyclodextrin-based gene delivery systems. Chem Soc Rev 2011; 3: 1586-1608.
18. Li J, Loh XJ,. Cyclodextrin-based supramolecular architectures: syntheses, structures, and applications for drug and gene delivery. Adv Drug Deliv Rev 2008; 9: 1000-1017.
19. Hatzi P, et al. Integrity of liposomes in presence of cyclodextrins: effect of liposome type and lipid composition. Int J Pharm 2007; 1-2: 167-176.
20. Gillet A, et al. Development of a new topical system: drug-in-cyclodextrin-in-deformable liposome. Int J Pharm 2009; 1-2: 174-180.
21. Yang M, et al. Biodegradable nanoparticles composed entirely of safe materials that rapidly penetrate human mucus. Angew Chem Int Ed 2011; 50: 2597-2600.
22. Li X, et al. Novel mucus-penetrating liposomes as a potential oral drug delivery system: preparation, in vitro characterization, and enhanced cellular uptake. Int J Nanomedicine 2011; 6: 3151-3162.
23. Ouyang DF, et al. Structure, dynamics, and energetics of siRNA-cationic vector complexation: a molecular dynamics study. J Phys Chem B 2010; 28: 9220-9230.
24. Wang X, et al. Preparation, characterization, pharmacokinetics, and bioactivity of honokiol-in-hydroxypropyl-β-cyclodextrin-in-liposome. J Pharm Sci 2011; 8: 3357-3364.
25. Piel G, et al. Betamethasone-in-cyclodextrin-in-liposome: the effect of cyclodextrins on encapsulation efficiency and release kinetics. Int J Pharm 2006; 1-2: 75-82.
26. Kostewicz ES, et al. Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine. J Pharm Pharmacol 2004; 1: 43-51.
27. Andrieux K, et al. Solubilisation of dipalmitoylphosphatidylcholine bilayers by sodium taurocholate: a model to study the stability of liposomes in the gastrointestinal tract and their mechanism of interaction with a model bile salt. Eur J Pharm Biopharm 2009; 2: 346-355.
28. Lu JL, et al. Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice. Eur J Pharm Biopharm 2008; 3: 899-907.
29. Cui J, et al. Enhancement of oral absorption of curcumin by self-microemulsifying drug delivery systems. Int J Pharm 2009; 1-2: 148-155.
30. Karine A, et al. Insertion and partition of sodium taurocholate into egg phosphatidylcholine vesicles. Pharm Res 2004; 8: 1505-1516.
31. Shigeki T, et al. Tacrolimus is a class ?Low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. J Pharm Sci 2001; 91: 719-729.
32. Tamura S, et al. The site-specific transport and metabolism of tacrolimus in rat small intestine. J Pharmacol Exp Ther 2003; 1: 310-316.
33. Nassar T, et al. A novel nanocapsule delivery system to overcome intestinal degradation and drug transport limited absorption of P-glycoprotein substrate drugs. Pharm Res 2008; 9: 2019-2029.
34. Nassar T, et al. Novel double coated nanocapsules for intestinal delivery and enhanced oral bioavailability of tacrolimus, a P-gp substrate drug. J Control Release 2009; 1: 77-84.
35. Sonaje K, et al. In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery. Biomaterials 2009; 12: 2329-2339.
36. Agüeros M, et al. Bioadhesive properties and biodistribution of cyclodextrin-poly(anhydride) nanoparticles. Eur J Pharm Sci 2009; 3-4: 231-240.
37. Makhlof A, et al. In vitro and in vivo evaluation of WGA-carbopol modified liposomes as carriers for oral peptide delivery. Eur J Pharm Biopharm 2011; 2: 216-224.
38. Thirawong N, et al. Improved intestinal absorption of calcitonin by mucoadhesive delivery of novel pectin-liposome nanocomplexes. J Control Release 2008; 3: 236-245.
39. Maria Teresa F, et al. Computer-aided molecular modeling techniques for predicting the stability of drug-cyclodextrin inclusion complexes in aqueous solutions. Chem Phys Lett 2002; 358: 383-390.
40. Niu M, et al. Liposomes containing glycocholate as potential oral insulin delivery systems: preparation, in vitro characterization, and improved protection against enzymatic degradation. Int J Nanomedicine 2011; 6: 1155-1166.
41. Parmentier J, et al. Stability of liposomes containing bio-enhancers and tetraether lipids in simulated gastro-intestinal fluids. Int J Pharm 2011; 1-2: 210-217.
42. Guan P, et al. Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt. Int J Nanomedicine 2011; 6: 965-974.
43. Rejman J, et al. Role of clathrin- and caveolae-mediated endocytosis in gene transfer mediated by lipo- and polyplexes. Mol Ther 2005; 3: 468-474.
44. Yang M, et al. Biodegradable nanoparticles composed entirely of safe materials that rapidly penetrate human mucus. Angew Chem Int Ed Engl 2011; 11: 2597-2600.